Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies

British Journal of Cancer

Volumn 95, Issue 5, 2006, Pages 627-633

  De Graeff, P ^a   Hall, J ^b   Crijns, A P G ^a   De Bock, G H ^a   Paul, J ^b   Oien, K A ^b   Ten Hoor, K A ^a   De Jong, S ^a   Hollema, H ^a   Bartlett, J M S ^c   Brown, R ^b   Van Der Zee, A G J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Ovarian cancer; p53; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; ETOPOSIDE; MELPHALAN; PLATINUM DERIVATIVE; PROTEIN P53; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; GENE OVEREXPRESSION; GERMAN FEDERAL REPUBLIC; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METHODOLOGY; MULTIVARIATE ANALYSIS; OVARY CANCER; OVERALL SURVIVAL; PATIENT ASSESSMENT; POPULATION RESEARCH; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STANDARDIZATION; TISSUE MICROARRAY; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED KINGDOM; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; FEMALE; GENES, P53; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33748290046     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603300     Document Type: Article

References (47)

1. Allan LA, Campbell MK, Milner BJ, Eccles DM, Leonard RCF, Parkin DE, Millers ID, Lessells AM, Kitchener HC, Haites NE (1996) The significance of p53 mutation and over-expression in ovarian cancer prognosis. Int J Gynecol Cancer 6: 483-490
2. Anttila MA, Ji H, Juhola MT, Saarikoski SV, Syrjanen KJ (1999) The prognostic significance of p53 expression quantitated by computerized image analysis in epithelial ovarian cancer. Int J Gynecol Pathol 18: 42-51
3. Arts HJ, Van Der Zee AG, De Jong S, De Vries EG (2000) Options for modulation of drug resistance in ovarian cancer. Int J Gynecol Cancer 10: 47-52
4. Atkins D, Reiffen KA, Tegtmeier CL, Winther H, Bonato MS, Storkel S (2004) Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 52: 893-901
5. Bartel F, Taubert H, Harris LC (2002) Alternative and aberrant splicing of MDM2 mRNA in human cancer. Cancer Cell 2: 9-15
6. Buttitta F, Marchetti A, Gadducci A, Pellegrini S, Morganti M, Carnicelli V, Cosio S, Gagetti O, Genazzani AR, Bevilacqua G (1997) p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br J Cancer 75: 230-235
7. Camp RL, Charette LA, Rimm DL (2000) Validation of tissue microarray technology in breast carcinoma. Lab Invest 80: 1943-1949
8. Cancer Committee of the International Federation of Gynaecology and Obstetrics (1986) Staging announcement: FIGO Cancer Committee. Gynecol Oncol 25: 383-385
9. Crawford SC, Vasey PA, Paul J, Hay A, Davis JA, Kaye SB (2005) Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial. J Clin Oncol 23: 8802-8811
10. Crijns APG, Boezen HM, Schouten JP, Arts HJG, Hofstra RMW, Willemse PHB, Vries de EGE, Van Der Zee AG (2003) Prognostic factors in ovarian cancer: current evidence and future prospects. Eur J Cancer S 1: 127-145
11. Demers GW, Halbert CL, Galloway DA (1994) Elevated wild-type p53 protein levels in human epithelial cell lines immortalized by the human papillomavirus type 16 E7 gene. Virology 198: 169-174
12. Dressler LG, Geradts J, Burroughs M, Cowan D, Millikan RC, Newman B (1999) Policy guidelines for the utilization of formalin-fixed, paraffin-embedded tissue sections: the UNC SPORE experience. University of North Carolina Specialized Program of Research Excellence. Breast Cancer Res Treat 58: 31-39
13. Ferrandina G, Fagotti A, Salerno MG, Natali PG, Mottolese M, Maneschi F, De Pasqua A, Benedetti-Panici P, Mancuso S, Scambia G (1999) p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer. Br J Cancer 81: 733-740
14. Friedlander ML (1998) Prognostic factors in ovarian cancer. Semin Oncol 25: 305-314
15. Gillett CE, Springall RJ, Barnes DM, Hanby AM (2000) Multiple tissue core arrays in histopathology research: a validation study. J Pathol 192: 549-553
16. Hall J, Paul J, Brown R (2004) Critical evaluation of p53 as a prognostic marker in ovarian cancer. Expert Rev Mol Med 2004: 1-20
17. Hartmann LC, Podratz KC, Keeney GL, Kamel NA, Edmonson JH, Grill JP, Su JQ, Katzmann JA, Roche PC (1994) Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol 12: 64-69
18. Hoos A, Cordon-Cardo C (2001) Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations. Lab Invest 81: 1331-1338
19. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4: 844-847
20. Kristensen GB, Trope C (1997) Epithelial ovarian carcinoma. Lancet 349: 113-117
21. Lassus H, Leminen A, Lundin J, Lehtovirta P, Butzow R (2003) Distinct subtypes of serous ovarian carcinoma identified by p53 determination. Gynecol Oncol 91: 504-512
22. Lavarino C, Pilotti S, Oggionni M, Gatti L, Perego P, Bresciani G, Pierotti MA, Scambia G, Ferrandina G, Fagotti A, Mangioni C, Lucchini V, Vecchione F, Bolis G, Scarfone G, Zunino F (2000) p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol 18: 3936-3945
23. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88: 323-331
24. Lu X, Park SH, Thompson TC, Lane DP (1992) Ras-induced hyperplasia occurs with mutation of p53, but activated ras and myc together can induce carcinoma without p53 mutation. Cell 70: 153-161
25. Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, Clarke-Pearson DL, Iglehart JD, Bast Jr RC, Berchuck A (1991) Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 51: 2979-2984
26. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93: 387-391
27. Midgley CA, Lane DP (1997) p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 15: 1179-1189
28. Nakayama K, Takebayashi Y, Nakayama S, Hata K, Fujiwaki R, Fukumoto M, Miyazaki K (2003) Prognostic value of overexpression of p53 in human ovarian carcinoma patients receiving cisplatin. Cancer Lett 192: 227-235
29. Nenutil R, Smardova J, Pavlova S, Hanzelkova Z, Muller P, Fabian P, Hrstka R, Janotova P, Radina M, Lane DP, Coates PJ, Vojtesek B (2005) Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. J Pathol 207: 251-259
30. Nielsen JS, Jakobsen E, Holund B, Bertelsen K, Jakobsen A (2004) Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Cancer 14: 1086-1096
31. Prioleau J, Schnitt SJ (1995) p53 antigen loss in stored paraffin slides. N Engl J Med 332: 1521-1522
32. Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, Jones LA, El Naggar A, Minguillon C, Schonborn I, Reich O, Kreienberg R, Lichtenegger W, Press MF (2001) Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 7: 2984-2997
33. Righetti SC, Della TG, Pilotti S, Menard S, Ottone F, Colnaghi MI, Pierotti MA, Lavarino C, Cornarotti M, Oriana S, Bohm S, Bresciani GL, Spatti G, Zunino F (1996) A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 56: 689-693
34. Rosen DG, Huang X, Deavers MT, Malpica A, Silva EG, Liu J (2004) Validation of tissue microarray technology in ovarian carcinoma. Mod Pathol 17: 790-797
35. Schmoor C, Sauerbrei W, Schumacher M (2000) Sample size considerations for the evaluation of prognostic factors in survival analysis. Stat Med 19: 441-452
36. Scully RE (1999) Histological Typing of Ovarian Tumours. 2nd edn Berlin: Springer
37. Shahin MS, Hughes JH, Sood AK, Buller RE (2000) The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer 89: 2006-2017
38. Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279
39. Van Der Zee AG, Hollema H, Suurmeijer AJ, Krans M, Sluiter WJ, Willemse PH, Aalders JG, De Vries EG (1995) Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 13: 70-78
40. Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB (2004) Phase III randomized trial of docetaxel- carboplatin vs paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96: 1682-1691
41. Vasey PA, Jones NA, Jenkins S, Dive C, Brown R (1996) Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance. Mol Pharmacol 50: 1536-1540
42. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408: 307-310
43. Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW, Galloway DA (1996) Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 2: 72-79
44. Wang Y, Helland A, Holm R, Skomedal H, Abeler VM, Danielsen HE, Trope CG, Borresen-Dale AL, Kristensen GB (2004a) TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival. Br J Cancer 90: 678-685
45. Wang Y, Kringen P, Kristensen GB, Holm R, Baekelandt MM, Olivier M, Skomedal H, Hainaut P, Trope CG, Abeler VM, Nesland JM, Borresen-Dale AL, Helland A (2004b) Effect of the codon 72 polymorphism (c.215G > C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma. Hum Mutat 24: 21-34
46. World Health Organization (1979) Handbook for Reporting Results of Cancer Treatment. Geneva: World Health Organization
47. Zhang Y, Xiong Y, Yarbrough WG (1998) ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92: 725-734